1b. Patients on immunosuppressive therapies and their household contacts should receive the nonlive trivalent inactivated influenza vaccine, but not the live inhaled influenza vaccine. Conditional recommendation, with very low level of evidence.
Patients with IBD are at increased risk for acquiring influenza infection relative to age-matched patients without IBD. Furthermore, some patients with IBD who acquire influenza infection are more likely to experience hospitalization and co-infection with pneumonia (9) . Patients with IBD are at increased risk for pneumonia relative to age-matched patients without IBD (hazard ratio [HR]: 1.54, 95% confidence interval [CI]: 1.49-1.60); this risk is apparent among both Crohn's disease (CD) and ulcerative colitis (UC) (10) . Pneumococcal vaccination can be safely administered simultaneously with influenza vaccination, thus providing an opportunity to educate and target patients appropriate for pneumococcal vaccination during the flu season (11) . Data suggest that IBD patients should be tested for varicella exposure and be vaccinated if non-immune. Varicella vaccine is a live attenuated vaccine and is contraindicated 1-3 months before start of biologics and if on one of these agents. The Infectious Diseases Society of America (IDSA) clinical practice guideline states that the administration of varicella vaccine can be considered for non-varicella-immune patients who are receiving long-term, low-dose immunosuppression (14) .
HERPES ZOSTER VACCINATION

YELLOW FEVER VACCINATION Recommendation
5.
Patients with IBD who are immunosuppressed and traveling to endemic areas for yellow fever should consult with a travel medicine or infectious disease specialist before travel.
Conditional recommendation, with very low level of evidence.
The yellow fever vaccine is a live attenuated vaccine; no alternative inactivated form of the vaccine is available. These patients should not undergo yellow fever vaccination, as there is a risk of developing a serious adverse event, specifically yellow fever vaccine-associated viscerotropic disease, which is a systemic disease associated with multi-organ failure and death.
If the patient requests to stop their immunosuppressive therapy to receive the vaccine, experts feel that the minimal time before the safe administration of the vaccine can be up to 3 months depending on the type of immunosuppressive regimen. The immunosuppressive treatment should not be restarted earlier than 4 weeks after vaccination (15) . Meningococcal vaccines are inactivated and can be administered to all IBD patients regardless of immunosuppression (16) . 1. Vaccines should be administered before planned immunosuppression if feasible (strong, moderate). 2. Live vaccines should be administered ≥4 weeks before immunosuppression (strong, low) and should be avoided within 2 weeks of initiation of immunosuppression (strong, low). 3. Inactivated vaccines should be administered ≥2 weeks before immunosuppression (strong, moderate) (14, 17) . The European Crohn's and Colitis Organization states "given the excess risk demonstrated in various other contexts of immunosuppression, it is currently recommended that all women with IBD, particularly those receiving immunosuppressants, strictly adhere to a screening program of cervical surveillance and undergo vaccination against HPV, when appropriate" (21) .
LIVE VACCINATIONS IN HOUSEHOLD MEMBERS OF IMMUNOSUPPRESSED IBD PATIENTS
TETANUS-DIPHTHERIA-ACELLUAR PERTUSSIS, HAV, HBV, AND HPV VACCINATIONS
SCREENING FOR DEPRESSION AND ANXIETY
Recommendation
Screening for depression and anxiety is recommended in patients with IBD. Conditional recommendation, low level evidence.
The etiology of IBD and disease activity following periods of remission is complex and likely involves an interaction between multiple factors. Psychological stress has been reported by both caregivers and patients to exacerbate disease. Addressing or at least identifying these issues in patients can be important for disease management and optimizing the chance for good outcomes (22) . 12b. IBD patients on immunomodulators (6-mercaptopurine or azathioprine) should undergo screening for NMSC while using these agents, particularly over the age of 50 years. Strong recommendation with low level of evidence.
It is suggested that all individuals who are initiating immunosuppression therapy for the treatment of IBD should use sunscreen that is protective against ultraviolet (UV) A and UVB light as well use sun-protective clothing. It is suggested that all IBD patients should follow a program of sun protection and dermatological surveillance, which considers other non-IBD-related risk factors for skin cancer development (23, 24) .
SCREENING FOR OSTEOPOROSIS
Recommendation 13. Patients with conventional risk factors for abnormal bone mineral density (BMD) with UC and CD should undergo screening for osteoporosis with BMD testing at the time of diagnosis and periodically after diagnosis. Conditional recommendation with very low level evidence Bone mineral density measurement (with a Dual-energy X-ray absorptiometry (DEXA) scan) is recommended in all patients starting oral corticosteroid therapy specifically in those who have used oral corticosteroid therapy for longer than 3 consecutive months at a dose ≥7.5 mg/day of prednisone-equivalent in the absence of baseline BMD measurement (25) .
SMOKING CESSATION IN PATIENTS WITH CD Recommendation
14.
Patients with CD who smoke should be counseled to quit.
Strong recommendation with low level evidence.
Although it is very important to take into account the preventive care for IBD patients, adherence to ≥1 additional component of preventive care was observed in 25% of patients reported by Jackson et al (26) . Recently, they reported that only 9% of patients on thiopurines underwent annual skin checks; 21% with IBD underwent a bone scan; 16% were reminded to have their influenza vaccine. Assessment of psychological wellbeing was undertaken in only 6% of patients. We as healthcare providers should increase the adherence to disease management guidelines to improve the quality of IBD outpatient management.
